Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R LaBadie

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|January 3, 2021
Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteersNaveed Shaik, Robert R LaBadie, Brian Hee, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2018
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I studyNaveed Shaik, Brian Hee, Hua Wei, et al.
British Journal of Clinical Pharmacology|March 1, 2018
Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteersM Naveed Shaik, Brian Hee, Hua Wei, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2014
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteersM Naveed Shaik, Robert R LaBadie, Dan Rudin, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial HypertensionXiang Gao, Melissa O'Gorman, Jack Cook, et al.
British Journal of Clinical Pharmacology|March 18, 2010
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentStanley Cohen, Samuel H Zwillich, Vincent Chow, et al.
Journal of Clinical Pharmacology|November 21, 2007
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjectsPing Liu, Grover Foster, Robert R LaBadie, et al.
Clinical Pharmacology in Drug Development|December 28, 2020
Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control StudyJoanna C Masters, Robert R LaBadie, Joanne Salageanu, et al.
Clinical Therapeutics|January 23, 2014
Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjectsBharat Damle, Gregory Duczynski, Barrett W Jeffers, et al.
Clinical Drug Investigation|February 23, 2022
The Effect of Hepatic Impairment on the Pharmacokinetics of DacomitinibJoseph Piscitelli, Joseph Chen, Robert R LaBadie, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|January 3, 2021
Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteersNaveed Shaik, Robert R LaBadie, Brian Hee, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2018
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I studyNaveed Shaik, Brian Hee, Hua Wei, et al.
British Journal of Clinical Pharmacology|March 1, 2018
Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteersM Naveed Shaik, Brian Hee, Hua Wei, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2014
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteersM Naveed Shaik, Robert R LaBadie, Dan Rudin, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
A Randomized, Open-Label, 3-Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial HypertensionXiang Gao, Melissa O'Gorman, Jack Cook, et al.
British Journal of Clinical Pharmacology|March 18, 2010
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentStanley Cohen, Samuel H Zwillich, Vincent Chow, et al.
Journal of Clinical Pharmacology|November 21, 2007
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjectsPing Liu, Grover Foster, Robert R LaBadie, et al.
Clinical Pharmacology in Drug Development|December 28, 2020
Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control StudyJoanna C Masters, Robert R LaBadie, Joanne Salageanu, et al.
Clinical Therapeutics|January 23, 2014
Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjectsBharat Damle, Gregory Duczynski, Barrett W Jeffers, et al.
Clinical Drug Investigation|February 23, 2022
The Effect of Hepatic Impairment on the Pharmacokinetics of DacomitinibJoseph Piscitelli, Joseph Chen, Robert R LaBadie, et al.
Pageof 4